BioSpace News Archive

Deals

Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences - June 9, 2019

Five Prime Therapeutics, Inc. announced that Aron Knickerbocker, Chief Executive Officer, is scheduled to present at the following two investor conferences:

June 9, 2019
·
1 min read
Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes

REWIND data showed a consistent effect in people with and without established cardiovascular disease

June 9, 2019
·
13 min read
Biotech Bay

Dulaglutide Reduces Cardiovascular Disease in People with Type 2 Diabetes

Presented at ADA’s Scientific Sessions, REWIND trial confirms dulaglutide reduces CVD risk regardless of CV history

June 9, 2019
·
6 min read
Genetown

Insulet’s Omnipod® Horizon™ Hybrid Closed-Loop System Improves Glycemic Control in Patients as Young as Two Years Old with Type 1 Diabetes

Pediatric Scientific Data for the Omnipod Horizon System Presented at the American Diabetes Association’s 79th Scientific Sessions

June 9, 2019
·
6 min read
Biotech Bay

Tandem Diabetes Care Reports Positive Results From Two Studies of the t:slim X2 Insulin Pump With Control-IQ Technology

Significant Time-in-Range Improvements Demonstrated in Adult and Pediatric Age Groups

June 9, 2019
·
10 min read
Biotech Bay

Type 1 Diabetes May Affect Brain Development, Beginning in Early Childhood

DirecNet study indicates youth with early-onset T1D have mild but detectable differences in brain development, based on research presented at the ADA’s Scientific Sessions

June 9, 2019
·
9 min read